Eyad Elkord

Abu Dhabi University — AE

Medicine · Health Sciences

48h-index12.3kcitations171works10.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(76), Immune Cell Function and Interaction(64), Immunotherapy and Immune Responses(38), T-cell and B-cell Immunology(35), Immune cells in cancer(34)

Publications171 total

Unmasking cancer’s silent saboteurs: T regulatory cells as therapeutic targets in immunotherapy
Expert Review of Clinical Immunology·2025
Targeting Tregs in T1DM: bridging heterogeneity, mechanisms, and clinical progress
Trends in Pharmacological Sciences·2025· 2 cited
TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies
Cell Death and Disease·2025· 13 citedOpen Access
Preface
Targeted Cancer Therapy Connect·2025
3-O-acetyl-11-keto-beta-boswellic acid (β-AKBA) and 11-keto-beta-boswellic acid (β-KBA) increase FoxP3 expression in CD4+ T regulatory cells
Fitoterapia·2025
Editorial: Community series in novel biomarkers in tumor immunity and immunotherapy, volume II
Frontiers in Immunology·2025Open Access
Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
Frontiers in Immunology·2025· 7 citedOpen Access
Investigating the functional role of BUB1B in aflatoxin B1-associated hepatocarcinogenesis
Toxicology·2025· 4 cited
Association of Expression of Immune Checkpoints in Tumor-Infiltrating CD4+ T Lymphocytes with Disease-Free Survival in Colorectal Cancer Patients
Targeted Cancer Therapy Connect·2025Open Access
Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets
Hepatology International·2025· 11 cited
The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy
Translational Oncology·2025· 14 citedOpen Access
Effect of boswellic acids on the expression of PD-1 and TIGIT immune checkpoints on activated human T cells
Fitoterapia·2025· 2 cited
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Molecular Cancer·2025· 91 citedOpen Access
Corrigendum to “Effect of Boswellic acids on T cell proliferation and activation” [Int. Immunopharmacol. 122 (2023) 110668]
International Immunopharmacology·2024· 3 citedOpen Access
Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation
Pharmaceuticals·2024· 1 citedOpen Access
Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials
Frontiers in Immunology·2024· 6 citedOpen Access
Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?
Vaccines·2024· 3 citedOpen Access
Editorial: Novel biomarkers in tumor immunity and immunotherapy
Frontiers in Immunology·2024· 3 citedOpen Access
What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?
Expert Review of Clinical Immunology·2024· 4 cited
Temporal patterns of cancer burden in Asia, 1990–2019: a systematic examination for the Global Burden of Disease 2019 study
The Lancet Regional Health - Southeast Asia·2024· 39 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Salman M. Toor(16), Varun Sasidharan Nair(14), Reem Saleh(9), Rowaida Z. Taha(7), Peter L. Stern(5), Robert E. Hawkins(5), Nehad M. Alajez(5), Bassam R. Ali(5), Haytham El Salhat(5), Azharuddin Sajid Syed Khaja(5), Belal Chaudhary(4), Yazan S. Khaled(4), Basil J. Ammori(4), Hibah Shaath(4), Deborah J. Burt(3), Radhakrishnan Vishnubalaji(3), Khaled Murshed(3), Mohamed Abu Nada(3), Pramod Darvin(2), Terry Lichtor(2)